PLUR (34) SCLX (40) DYAI (31) ABOS (33) ⌘ Pro Terminal →

Jasper Therapeutics Inc. (JSPR) — RQD Stock Rating Cockpit

$0.52 -2.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.52

Jasper Therapeutics Inc. (JSPR) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $17.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on JSPR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is JSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Jasper Therapeutics Inc. (NASDAQ: JSPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.52 (-2.22% 1D, market cap $17.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, JSPR ranks #577 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does JSPR compare to PLUR and SCLX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), JSPR carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLUR (Pluri Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, JSPR leads on earnings multiple (N/A) while JSPR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for JSPR?

▼

Per JSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001788028), Jasper Therapeutics Inc. generated $0 in revenue, -$76 in net income, and -$77.2M in free cash flow against $35.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.52 (-0.59%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JSPR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY JSPR SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.50+0% Next Q

Q2 (-2Q)

Grade E$0.50+4% Next Q

Q3 (-1Q)

Grade E$0.52+0% Next Q

Current

Grade D-$0.52-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a JSPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While JSPR currently carries a cautious 36/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.59) and Max Pain ($0.55) forces dealer call-delta covering toward $2.54.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $JSPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “JSPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

44.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE10% OF RANGE

L: $0$0.52H: $2

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on JSPR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (37)

14/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like JSPR

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JSPR)

✓Walkthrough of JSPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

JSPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.47%⚡ TESTING RESISTANCE

2026-11-03O $0.53H $0.53L $0.52C $0.52VOL 396.1K

RES: $0.55SUP: $0.44SMA50: $0.59SMA200: $0.84

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JSPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JSPR Butterfly Map → + Track JSPR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on JSPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JSPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for JSPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JSPR)

Health Care Rank #577 of 1016 ⚔️ PLUR vs JSPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JSPR vs. PLUR, SCLX, DYAI, ABOS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Jasper Therapeutics Inc. (JSPR) ranks #577 by composite RQD confidence (36/100, grade D-) and #839 by equity capitalization ($17.3M). Within this direct 5-issuer industry benchmark cohort, JSPR leads on earnings valuation at N/A trailing P/E, while JSPR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with JSPR at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
JSPR ACTIVE Jasper Therapeutics Inc.	D-	36/100	—	—	-35.0%	-2.22%	$17.3M	Benchmark Subject
PLUR Pluri Inc.	E	34/100	—	49.0%	-35.0%	+3.33%	$16.7M	/plur-vs-jspr →
SCLX Scilex Holding Company	D-	40/100	—	96.0%	-35.0%	-10.19%	$15.7M	/sclx-vs-jspr →
DYAI Dyadic International Inc.	E	31/100	—	24.9%	-35.0%	+5.32%	$15.2M	/dyai-vs-jspr →
ABOS Acumen Pharmaceuticals Inc.	E	33/100	—	—	-35.0%	-90.82%	$15.2M	/abos-vs-jspr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001788028

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jasper Therapeutics Inc. (JSPR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$76, operating cash flow of -$77.2M, and free cash flow of -$77.2M (-23.3% YoY). On the balance sheet, JSPR closed FY2025 with $35.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$76	-$77.2M	-$77.2M	$35.8M	—
FY2024 (FY)	2024-12-31	$0	-$71.3M	-$62.6M	-$62.6M	$79.9M	—
FY2023 (FY)	2023-12-31	$0	-$64.5M	-$52.1M	-$52.1M	—	—

3. JSPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does JSPR compare to PLUR and SCLX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for JSPR?

Where is JSPR trading relative to its 50-day, 200-day, and 52-week technical levels?

JSPR last traded at $0.52 (-2.22% on volume of 396,132 shares), positioning the stock -11.86% below its 50-day simple moving average ($0.59) and -38.10% below its 200-day simple moving average ($0.84). Across its 52-week range of $0.31 to $2.42, JSPR sits at the 10.0% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.59).

JSPR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell JSPR stock right now?

Jasper Therapeutics Inc. (JSPR) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is JSPR's 12-month price target and RQD AI Jury consensus?

JSPR's 12-month base price target is $0.47 (range $0.37 to $2.54), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: JSPR RQD Cockpit JSPR 12M Forecast JSPR Earnings & Move JSPR Dividends & DRIP JSPR Insiders & 13F JSPR Whale Options JSPR Profit Sankey JSPR News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

JSPR — Jasper Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:50:14Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, JSPR scores 37 out of 100, earning a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 4 of 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F flow scores 10 of 20 for institutional accumulation and options positioning, a moderate reading. Insider conviction scores 5 of 20 based on SEC Form 4 and Congressional PTR cluster flow, the weakest signal after the cash engine. Macro regime fit scores 8 of 20 with a beta of 1.0 and sector sensitivity noted. Forensic balance sheet scores 10 of 20, reflecting an Altman Z of 2.5, a Piotroski F of 2/9, and a debt-to-equity of 0.5.

For a prospective investor evaluating the stock today, the rating points to a company whose operating losses and negative cash flow are the central factual concern. Any upside case would depend on developments not captured in the reported cash-flow line, and the source data does not quantify such developments. The rating is a descriptive summary of the supplied metrics, not a recommendation.

Business

Jasper Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, its market capitalization is $0.0B on a rounded basis, consistent with the $17.7M figure in market data. Per the news wire, the company's clinical program includes vensobafusp alfa (KP104) in IgA Nephropathy, with a Phase 2 renal basket study cohort reported as having completed enrollment. The source data does not describe customers, revenue model, or commercialization arrangements; revenue is reported as $0.0M across the financial periods provided.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-83.9M	$-0.0M	N/A	$-77.2M	$28.7M	N/A
FY 2024	$0.0M	$-76.2M	$-71.3M	N/A	$-62.6M	$71.6M	N/A
FY 2023	$0.0M	$-68.9M	$-64.5M	N/A	$-52.1M	N/A	N/A

Per the SEC financials, reported revenue is $0.0M in each period, and operating losses widened from $-68.9M (FY 2023) to $-83.9M (FY 2025). Gross, operating, and net margins are each reported as 0%, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, both per the Roarable RQD rating. Reported cash declined from $71.6M (FY 2024) to $28.7M (FY 2025), and debt is listed as N/A in the financial periods, with a debt-to-equity of 0.5 per the forensic balance sheet pillar.

Recent Catalysts & News Wire Analysis

Phase 2 IgAN enrollment: A news item reports completion of enrollment in the first cohort of the Phase 2 Renal Basket Study evaluating vensobafusp alfa (KP104) in IgA Nephropathy; a separate item states interim data is due by year-end 2026.
Reverse split vote: A news item reports stockholders have until December 31, 2026 to decide on a reverse split.
Warrant tender offer: A news item reports commencement of an offer to purchase outstanding warrants.
Estimates coverage: A TradingView item covers JSPR estimates; no estimate values are provided in the source data.
Risk watch: The reverse split item and the 52-week low of $0.31 against a current price of $0.53 are the most prominent risk-related items in the source data.
Proprietary signals: The Butterfly Supply-Chain Graph reports no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is reported as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. Within the source data alone, the company's status as a clinical-stage-style issuer (inferred from enrolling trial cohorts and reporting no revenue) would make trial timing and financing the primary ripple channels, but the source data does not confirm the company's stage and this should not be treated as a finding.

Open Questions

What is the company's cash runway given reported cash of $28.7M against FY 2025 free cash flow of $-77.2M?
What is the terms and status of the warrant tender offer and its effect on share count and dilution?
What are the reverse split ratio and the conditions under which the shareholder vote would proceed?
What does the interim IgAN data due by year-end 2026 need to show, and how would it be funded if results are unfavorable?
Why are FY 2023 cash and all debt figures reported as N/A, and what are the actual balance sheet liabilities?

JSPR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Jasper Therapeutics Inc. (JSPR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to JSPR Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 17h ago

Jasper Therapeutics(JSPR) Stock Options Chain | Quotes & News

Moomoo report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 20h ago

Stockholders give Jasper Therapeutics (JSPR) until December 31, 2026 to decide on a reverse split.

Stock Titan report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 23h ago

Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

Yahoo Finance report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Jasper Therapeutics, Inc. Estimates – NASDAQ:JSPR

TradingView report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

GlobeNewswire report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Jasper Therapeutics completes IgAN cohort enrollment; interim data due by year-end 2026

TradingView report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Jasper completes 18-patient study. Jasper Therapeutics stock is valued at USD 17.7 million

ad-hoc-news.de report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Kidney study cohort enrollment ends at Jasper Therapeutics (JSPR), with interim data expected by year-end 2026.

Stock Titan report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

JSPR Bull vs. Bear Conversation Board — What's Your Call at $0.52?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JSPR 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.47 (-11.3%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is JSPR (D- • RQD 37/100) a Buy at $0.53?

Welcome to the JSPR (Jasper Therapeutics Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.42 (-20.8%)

Spot @ $0.53

Pump the brakes on JSPR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on JSPR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Jasper Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.60 (+13.2%)

Spot @ $0.53

JSPR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on JSPR, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.53 (52-wk range $0.31 - $2.42), any beat on forward guidance forces shorts and underweight funds to chase.